# Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

> **NCT03214627** · NA · TERMINATED · sponsor: **Vifor Fresenius Medical Care Renal Pharma** · enrollment: 88 (actual)

## Conditions studied

- Anemia
- End Stage Renal Disease

## Interventions

- **DEVICE:** Anemia Control Model (ACM)
- **DRUG:** IV iron
- **DRUG:** Erythropoiesis-Stimulating Agent (ESA)

## Key facts

- **NCT ID:** NCT03214627
- **Lead sponsor:** Vifor Fresenius Medical Care Renal Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-10
- **Primary completion:** 2019-05-21
- **Final completion:** 2019-05-21
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Standard clinical practice at site caused unforeseen issues for the use of the ACM
- **Last updated:** 2020-01-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03214627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03214627, "Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03214627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*